Angiotensin(1 –7) Improves Islet Function in Diabetes Through Reducing JNK/Caspase-3 Signaling
Horm Metab Res 2022; 54: 250-258 DOI: 10.1055/a-1796-9286The aim of this study is to investigate whether Angiotensin (1–7), the
physiological antagonist of Angiotensin II (AngII), has antidiabetic activity
and the possible mechanism. Male Wistar rats were randomly divided into 3
groups: control group fed the normal diet, DM group fed high-fat diet and
injected with STZ, and Angiotensin (1–7) group receiving injection of
STZ followed by Angiotensin (1–7) treatment. Serum Ang II, fasting blood
glucose, insulin, HOMA-IR, and HOMA-beta were determined in control, diabetes
and Angiotensin (1–7) groups. The increased AngII and insulin resistance
in diabetes group were accompanied by changes in islet histopathology. However,
Angiotensin (1–7) improved the islet function and histopathology in
diabetes without affecting the level of AngII. Western blot confirmed that
Angiotensin (1–7) decreased the cleaved caspase 3 levels in pancreas of
DM. The increased expression of JNK, Bax, and Bcl2 genes under diabetic
conditions were partially reversed after Angiotensin (1–7)
administration in pancreas. Immunofluorescence analysis showed that p-JNK was
markedly increased in islet of DM rats, which was markedly alleviated after
Angiotensin (1–7) treatment. Furthermore, Angiotensin (1–7)
reversed high glucose(HG...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Liu, Jing Li, Xing Wang, Xiaoyan Peng, Lina Song, Guoning He, Junhua Tags: Original Article: Endocrine Research Source Type: research